CAS 6742-12-7|formycin A
Introduction：Basic information about CAS 6742-12-7|formycin A, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | formycin A | ||
|---|---|---|---|
| CAS Number | 6742-12-7 | Molecular Weight | 285.25700 |
| Density | 1.771g/cm3 | Boiling Point | 709.5ºC at 760 mmHg |
| Molecular Formula | C10H13N5O4 | Melting Point | 153-155ºC |
| MSDS | ChineseUSA | Flash Point | 382.9ºC |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | formycin A |
|---|---|
| Synonym | More Synonyms |
formycin A BiologicalActivity
| Description | Formycin A (NSC 102811), a purine nucleoside antibiotic, is a potent human immunodeficiency virus type 1 (HIV-1) inhibitor with an EC50 of 10 μM. Formycin A shows antitumor and antiviral activities[1][2]. |
|---|---|
| Related Catalog | Research Areas >>CancerSignaling Pathways >>Anti-infection >>HIVResearch Areas >>Infection |
| Target | HIV-1:10 μM (EC50) |
| In Vitro | Formycin A (NSC 102811; 1 μM, 5 μM, 10 μM) antagonizes Zidovudine (AZT; a dideoxynucleoside chain terminator). |
| References | [1]. Dapp MJ , et al. Discovery of novel ribonucleoside analogs with activity against human immunodeficiency virus type 1.J Virol. 2014 Jan;88(1):354-63. [2]. Zhang M, et al. Comparative Investigation into Formycin A and Pyrazofurin A Biosynthesis Reveals Branch Pathways for the Construction of C-Nucleoside Scaffolds. Appl Environ Microbiol. 2020 Jan 7;86(2). |
Chemical & Physical Properties
| Density | 1.771g/cm3 |
|---|---|
| Boiling Point | 709.5ºC at 760 mmHg |
| Melting Point | 153-155ºC |
| Molecular Formula | C10H13N5O4 |
| Molecular Weight | 285.25700 |
| Flash Point | 382.9ºC |
| Exact Mass | 285.10700 |
| PSA | 159.63000 |
| Index of Refraction | 1.803 |
| InChIKey | KBHMEHLJSZMEMI-KSYZLYKTSA-N |
| SMILES | Nc1ncnc2c(C3OC(CO)C(O)C3O)[nH]nc12 |
| Storage condition | -20°C |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 1 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 400 mg/kg
- TOXIC EFFECTS :
- Blood - hemorrhage Blood - changes in spleen Blood - other changes
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 125 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 250 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 20 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 165 mg/kg/5D-I
- TOXIC EFFECTS :
- Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases Related to Chronic Data - death
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Parenteral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 200 mg/kg/8D-I
- TOXIC EFFECTS :
- Related to Chronic Data - death
MUTATION DATA - TYPE OF TEST :
- Mutation test systems - not otherwise specified
- TEST SYSTEM :
- Rodent - mouse Leukocyte
- DOSE/DURATION :
- 25700 ug/L
- REFERENCE :
- JMCMAR Journal of Medicinal Chemistry. (American Chemical Soc., Distribution Office Dept. 223, POB POB 57136, West End Stn., Washington, DC 20037) V.6- 1963- Volume(issue)/page/year: 30,481,1987
- TYPE OF TEST :
- Mutation test systems - not otherwise specified
- TEST SYSTEM :
- Rodent - mouse Leukocyte
- DOSE/DURATION :
- 25700 ug/L
- REFERENCE :
- JMCMAR Journal of Medicinal Chemistry. (American Chemical Soc., Distribution Office Dept. 223, POB POB 57136, West End Stn., Washington, DC 20037) V.6- 1963- Volume(issue)/page/year: 30,481,1987
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Hazard Codes | Xn |
| Risk Phrases | 22 |
| Safety Phrases | 22-24/25 |
| RIDADR | NONH for all modes of transport |
| RTECS | UR0719000 |
Articles6
More Articles| Purine nucleoside metabolism in the erythrocytes of patients with adenosine deaminase deficiency and severe combined immunodeficiency. J. Clin. Invest. 57(4) , 1025-35, (1976) Deficiency of erythrocytic and lymphocytic adenosine deaminase (ADA) occurs in some patients with severe combined immunodeficiency disease (SCID). SCID with ADA deficiency is inherited as an autosomal... | |
| The riddle of formycin A insulinotropic action. Biochem. Mol. Med. 57(1) , 47-63, (1996) Formycin A augments insulin release evoked by glucose (5.6 mm or more), this effect not being rapidly reversible. The mechanism responsible for the insulinotropic action of formycin A was investigated... | |
| Tautomerism of the nucleoside antibiotic formycin, as studied by carbon-13 nuclear magnetic resonance. J. Am. Chem. Soc. 95(14) , 4761-2, (1973) |
Synonyms
| formycin |
| FORMYCIN A MONOHYDRATE |
| FORMYCIN MONOHYDRATE |
| 7-AMINO-3-β-D-RIBOFURANOSYL-1H-PYRAZOLO[4,3-D]PYRIMIDINE MONOHYDRATE |
| 8-AZA-9-DEAZAADENOSINE MONOHYDRATE |
